TOP-REAL Study Explores Digital Monitoring for Early Toxicity Detection in Breast Cancer Treatment
Introduction
The evolution of cancer treatment has been remarkable, particularly in the context of HER2-positive metastatic breast cancer. A new phase in this journey is marked by the ongoing TOP-REAL study, spearheaded by the academic research group Solti in collaboration with Unicancer from France and WSG from Germany. The study focuses on the integration of digital monitoring tools into patient care aimed at early detection of toxicities, potentially enhancing treatment continuity and patient quality of life.
A Revolutionary Approach to Monitoring
Presenting their findings at the ESMO AI Digital Oncology 2026, the research team described a proactive monitoring model that leverages electronic patient-reported outcomes (ePROs), pulse oximetry, and continuous physiological data captured through smartwatches. This multifaceted detection system allows healthcare professionals to receive alerts about abnormal symptoms or changes, prompting earlier clinical assessments than traditional visit-based models would allow.
Dr. Cristina Saura, the lead researcher and a prominent figure at Vall d'Hebron University Hospital, shared insights into the philosophy behind TOP-REAL: "We aim to enable patients not only to benefit from advancements that improve their disease control but also to enhance their quality of life during treatment. Our dual focus is on improving clinical outcomes while placing patients’ quality of life at the center of care."
Study Design
TOP-REAL is set to engage approximately 300 patients across 60 centers in Spain, France, and Germany, an initiative that aims to generate evidence closer to clinical routine practices. The study will not only include profiles often underrepresented in regulatory trials but will also explore the management of toxicities associated with the investigational treatment Trastuzumab Deruxtecan (T-DXd) combined with Pertuzumab.
Among the toxicities evaluated will be interstitial lung disease and pneumonitis linked to T-DXd, making the regular assessment of oxygen saturation through pulse oximetry vital. Routine stress tests will also be conducted to determine if certain physiological changes warrant earlier medical evaluations.
Addressing Diverse Patient Profiles
One of the groundbreaking aspects of TOP-REAL is its emphasis on including diverse patient profiles, particularly those with active brain metastases or less-than-optimal performance statuses. This approach is designed to provide insights relevant to a broader spectrum of clinical practices and to optimize management capabilities for varied patient backgrounds.
Dr. Santiago Escrivà, another key investigator, highlighted the significance of this inclusivity: "This study aids in the practical implementation of T-DXd and Pertuzumab treatment by allowing us to better understand how to expand access to this novel treatment and manage potential toxicities effectively."
An Innovative, Patient-Centered Model
The integration of digital tools allows for near-constant monitoring of patient conditions. Utilizing mobile applications like CANKADO or Resilience (depending on the location), combined with electronic reporting systems, patients can share their symptoms and physiological updates between hospital visits. The proactive alerts generated may drastically alter the standard cancer care model, shifting from waiting for patients to report issues during visits to being able to anticipate and manage them on a continuous basis.
Dr. Inês Vaz-Luis, a leading co-investigator, elaborated on the innovative nature of TOP-REAL, stating, "This study uniquely presents an opportunity to integrate innovative, patient-centered supportive care pathways into clinical trials. It allows patients access to effective new treatments while potentially improving their overall treatment experience and outcomes."
Broader Implications
Beyond toxicity management, TOP-REAL will assess the feasibility and safety of restarting T-DXd for selected patients, alongside analyses of tumor biopsies and blood samples to identify biomarkers related to treatment response and toxicity. The overarching goal is to preserve and enhance patient quality of life while extending their treatment benefits.
This cooperative effort across European borders underscores the importance of integrating innovations into clinical routines, demonstrating that effective cancer management goes beyond merely the medical outcomes—it significantly encompasses the overall patient experience.
As the study progresses and produces insights, it could pave the way for implementing cutting-edge digital care solutions in various healthcare systems, standardizing quality support across diverse healthcare environments.
Conclusion
The TOP-REAL study represents a significant advancement in how medical science approaches the treatment of HER2-positive metastatic breast cancer. By intertwining digital tools with patient care, researchers aim not only to enhance treatment outcomes but also to fundamentally transform patient experience throughout their cancer journeys.
In conclusion, the TOP-REAL study is poised to redefine the landscape of oncological care for HER2-positive breast cancer patients, and its findings may have far-reaching implications in the field of cancer care and beyond.